ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PI3Kalpha
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PI3Kalpha
16
trial(s) found.
NCT06736704
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
Endometrial cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
Colorectal cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06208657
Advanced
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ cancer therapy,PI3Kalpha-targeting
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05894239
Advanced
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (
INAVO122
)
PI3K alpha inhibitor
placebo
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NCT05563220
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (
ELEVATE
)
selective estrogen receptor degrader
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NCT05508906
Advanced
Phase 1
Recruiting
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor Everolimus in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer (
OP-1250-003
)
CDK4/6 inhibitor
PI3K alpha inhibitor
complete estrogen receptor antagonist
mTORC1 inhibitor
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05501886
Advanced
Phase 3
Recruiting
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy (
VIKTORIA-1
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast Private Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5011 - Woodville South - The Queen Elizabeth Hospital
NA
NA
NCT05216432
Advanced
Phase 1
Recruiting
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (
RLY-2608-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
selective estrogen receptor degrader
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
Endometrial cancer
HER2-negative breast cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ cancer therapy,PI3Kalpha-targeting
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04449874
Advanced
Phase 1
Recruiting
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (
GO42144
)
KRAS G12C inhibitor
+ cancer therapy,PI3Kalpha-targeting
Colorectal cancer
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03970447
Advanced
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ cancer therapy,PI3Kalpha-targeting
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
+ cancer therapy,PI3Kalpha-targeting
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
+ cancer therapy,PI3Kalpha-targeting
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05646862
Advanced
Phase 3
Active not recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy (
INAVO121
)
PI3K alpha inhibitor
selective estrogen receptor degrader
+ cancer therapy,PI3Kalpha-targeting
Breast cancer
NOT HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Active not recruiting (1)
Recruitment Country and State
NSW (13)
VIC (13)
WA (10)
QLD (6)
SA (6)
NZ (2)
TAS (2)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (4)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Advanced (16)
Paediatric (1)
Cancer Therapy Class
PI3Kalpha
100%
oestrogen axis
56%
ER
50%
mTOR
44%
mTORC1
44%
CDK4
44%
CDK6
44%
PD-1/PD-L1
31%
PI3K
25%
mTORC2
25%
PD-L1
25%
ERBB2
19%
PI3K-delta
19%
AKT
19%
VEGF
19%
CDK7
13%
EGFR
13%
KRAS
13%
KRAS G12C
13%
CDK4 selective
6%
TIGIT
6%
SHP2
6%
FGFR
6%
FGFR1
6%
FGFR1/2/3
6%
FGFR2
6%
FGFR3
6%
FGFR4
6%
KIT
6%
PDGFR
6%
RET
6%
VEGFR
6%
CD40
6%
IL-6
6%
LIV1
6%
Trop2
6%
CTLA4
6%
PARP
6%
PD-1
6%
XPO1
6%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
NA
5042 - Bedford Park - Flinders Medical Centre (4)
6009 - Nedlands - Linear Clinical Research (3)
3168 - Clayton - Monash Medical Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2109 - North Ryde - Macquarie University Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3004 - Melbourne, Southbank - Alfred Health (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
7000 - Hobart - Royal Hobart Hospital (2)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
6009 - Perth - Perth Children's Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4215 - Southport - Gold Coast Private Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3066 - Epping - Northern Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Breast adenocarcinoma
Endometrial cancer
Gynaecological cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Central nervous system cancer
Neurological cancer
Colorectal adenocarcinoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
ER-positive breast cancer
HER2-negative breast cancer
HR-positive breast cancer
Glioma
High-grade glioma
Malignant glioma
HER2-positive breast cancer
RAS-mutant colorectal cancer
Glioblastoma
Anaplastic astrocytoma
Low-grade glioma
Carcinoma
Endometrial stromal sarcoma
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Leiomyosarcoma
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian granulosa cell tumour
Ovarian serous carcinoma
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Sarcoma
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy